Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo - Archive ouverte HAL Access content directly
Journal Articles OncoImmunology Year : 2019

Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

(1) , (1) , (2) , (2) , (3) , (3) , (3)
1
2
3

Abstract

Epithelial ovarian cancer (EOC) represents 5% of human gynecologic cancers in the world, is hetero- geneous and highly invasive with a dismal prognosis (5 year-survival rate <35%). Diagnosis of EOC is frequently made at advanced stages and, despite aggressive treatments combining surgery and che- motherapy, fatal relapse rapidly occurs and is accompanied by a peritoneal carcinosis. In this context, novel therapeutical advances are urgently required. Adoptive transfer(s) of immune effector cells, including allogeneic human Vγ9Vδ2 T lymphocytes, represent attractive targets for efficiently and safely tracking tissue-invading tumor cells and controlling tumor dissemination in the organism. Our study describes the establishment of robust and physiological orthotopic model of human EOC in mouse, that includes surgical resection (ovariectomy) and chemotherapy, which are ineluctably accompanied by a fatal peritoneal carcinosis recurrence. Through a complementary set of in vitro and in vivo experiments, we provide here a preclinical proof of interest of the antitumor efficiency of adoptive transfers of allogeneic human Vγ9Vδ2 T lymphocytes against EOC, in association with surgical debulking and standard chemotherapies (i.e., taxanes and platinum salts). Moreover, our results indicate that chemo- and immunotherapies can be combined to improve the antitumor efficiency of immunotherapeutic lines. Altogether, these results further pave the way for next-generation antitumor immunotherapies, based on local administrations of human allogeneic human Vγ9Vδ2 T lymphocytes, in association with standard treatments.
Fichier principal
Vignette du fichier
Joalland_EOC_OncoImm2019.pdf (3.62 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-02437297 , version 1 (13-01-2020)

Identifiers

Cite

Noémie Joalland, Laura Lafrance, Thibauld Oullier, Severine Marionneau-Lambot, Delphine Loussouarn, et al.. Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo. OncoImmunology, 2019, 8 (11), pp.e1649971. ⟨10.1080/2162402X.2019.1649971⟩. ⟨inserm-02437297⟩
49 View
92 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More